ERBB2 and breast carcinoma: In this study, we found near 80% of the BRCA1-deficient mouse mammary tumors are ER and PR double negative, while 60% of the tumors show detectable expression level of ERBB2 (Figure S2A), which is inconsistent with the human BRCA1 related breast cancers 16.